{"nctId":"NCT02982590","briefTitle":"Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus","startDateStruct":{"date":"2016-11","type":"ACTUAL"},"conditions":["Left Ventricular Thrombosis"],"count":27,"armGroups":[{"label":"warfarin sodium","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Warfarin Sodium"]},{"label":"apixaban","type":"EXPERIMENTAL","interventionNames":["Drug: Apixaban 5 MG Oral Tablet [ELIQUIS]"]}],"interventions":[{"name":"Apixaban 5 MG Oral Tablet [ELIQUIS]","otherNames":["ELIQUIS"]},{"name":"Warfarin Sodium","otherNames":["Coumadin"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Age 18 - 80 years old\n2. Presence of LV thrombus or spontaneous echo contrast (SEC) grade 3 or 4 (Patel VG 1996), with regional wall motion abnormalities\n3. HASBLED score less than 3\n4. No episodes of major bleeding in the past 6 months a) Major bleeding defined as i. episodes of bleeding with significant drop in haemoglobin(Hb)level of at least 2gm/dL - Includes upper and lower gastrointestinal bleed ii. The need for blood transfusion (pack cell) of at least 2 unit iii. Recent surgery with bleeding complications and lost of Hb as in (i) or (ii) iv. Any intracranial bleeds with neurological deficits\n\nExclusion Criteria:\n\n1. Patient with unstable arrhythmias and/or recurrent cardiogenic shock\n2. Patient with large ischemic stroke on recruitment-defined as involving \\>1/3 of cerebral hemisphere or deemed to have high chance of haemorrhagic transformation\n3. Patient with permanent pacemaker\n4. Patient who is post valve replacement therapy\n5. Patient who is pregnant.\n6. Patient with advanced kidney disease at stage V and not on dialysis (CrCl \\<15 mL/min)\n7. Patient with advanced liver disease with coagulopathy\n8. Patient with organized and old left ventricular thrombus","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change in Left Ventricular Thrombus (LVT) Size","description":"Percentage of change in left ventricular thrombus (LVT) size after 12 weeks of Warfarin or Apixaban treatment","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-61.45","spread":"43.95"},{"groupId":"OG001","value":"-65.08","spread":"31.34"}]}]}]},{"type":"SECONDARY","title":"Change of Left Ventricular Thrombosis (LVT) by More Than 50%","description":"Percentage of participants who achieved left ventricular thrombus (LVT) reduction more than 50% in both Warfarin and Apixaban arms.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.7","spread":null},{"groupId":"OG001","value":"61.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinically Definite Cardiac Embolic Ischemic Stroke","description":"Number of participants who showed evidence of clinically definite cardiac embolic ischemic stroke (focal neurological deficits persisting for more than 24 hours) confirmed by CT scan","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Life Threatening Bleeding","description":"Number of participants who experienced life threatening bleeding attributed to the use of anti-coagulation.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":13},"commonTop":["Epistaxis"]}}}